-
Mashup Score: 16
Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 20…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10The OncoAlert5k at SABCS24 - 2 day(s) ago
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our steps in for this 5k(Walk/RUN)
Source: oncoalert.m-pages.comCategories: General Medicine News, Hem/OncsTweet-
RT @OncoAlert: The Oncoalert 5k Homecoming at #SABCS24 JOIN US!! Register here: https://t.co/0wlsCQBKNb Space is Limited Thursday Dec 12,…
-
-
Mashup Score: 15
Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 20…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
RT @APCCC_Lugano: Results after Four Years of Screening for Prostate Cancer with PSA and MRI Out on @NEJM https://t.co/J2ty8ouL5b This…
-
-
Mashup Score: 15
Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 20…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
RT @APCCC_Lugano: Results after Four Years of Screening for Prostate Cancer with PSA and MRI Out on @NEJM https://t.co/J2ty8ouL5b This…
-
-
Mashup Score: 8167. Allison Rosen (12 Year Early Age Onset Colorectal Cancer Survivor and Patient Advocate) - 21 day(s) ago
Podcast Episode · INTERLUDE: Cancer Stories with Dr. Teplinsky · 11/01/2024 · 1 sec
Source: podcasts.apple.comCategories: General Medicine News, Hem/OncsTweet-
RT @drteplinsky: https://t.co/dWx8RMdtEI Excited to share my podcast 🎙️ conversation with @ARosen380 all about her story of being dx with…
-
-
Mashup Score: 6
Join this webinar on October 2, 19:00 CEST, where Bertrand Tombal and Fred Saad will discuss the results of the PEACE III trial and more, and the implications of these new data for daily clinical practice.
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
FREE WEBINAR TODAY Oct 2nd 7pm CET🇪🇺1pm EST🇺🇸 GET UP TO DATE on PEACE III in #ProstateCancer with Fred Saad 🇨🇦and @BertrandTOMBAL 🇧🇪 as presented at #ESMO24 🆓🆓🆓🆓🆓 https://t.co/Sba8YApYEp https://t.co/HGXmvrpJAk
-
-
Mashup Score: 5Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM - 2 month(s) ago
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
RT @ElisaAgostinett: Simultaneous publication in @NEJM ⬇️ @OncoAlert https://t.co/jTkFPH3rUi
-
-
Mashup Score: 17The OncoAlert Newsletter - 2 month(s) ago
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
Source: oncoalert.m-pages.comCategories: General Medicine News, Hem/OncsTweet-
A warm welcome to join the @OncoAlert 🚨Newsletter The Latest in Oncology, weekly, simple and delivered straight to your inbox. As always, For Colleagues...By Colleagues!! https://t.co/DjFxZIg4PM
-
-
Mashup Score: 5Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM - 2 month(s) ago
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
RT @ElisaAgostinett: Simultaneous publication in @NEJM ⬇️ @OncoAlert https://t.co/jTkFPH3rUi
-
-
Mashup Score: 5Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM - 2 month(s) ago
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
RT @ElisaAgostinett: Simultaneous publication in @NEJM ⬇️ @OncoAlert https://t.co/jTkFPH3rUi
-
RT @APCCC_Lugano: Results after Four Years of Screening for Prostate Cancer with PSA and MRI Out on @NEJM https://t.co/J2ty8ouL5b This…